Skip to main content

Advertisement

SpringerLink
Log in

A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Background

Upfront surgery is recommended in patients with potentially resectable pancreatic ductal adenocarcinoma (R-PDAC) by National Comprehensive Center Network (NCCN) guidelines. However, even among R-PDACs, there is a subset that demonstrates extremely poor prognosis. The purpose of this study was to identify preoperative prognostic factors for upfront surgical resection of R-PDACs.

Methods

The records of 278 consecutive patients with PDAC who underwent curative resection between 2001 and 2015 in a single institution were retrospectively reviewed. Preoperative factors to predict prognosis in patients with R-PDAC according to the NCCN guidelines were analyzed.

Results

Of the 278 patients who underwent resection, 153 R-PDACs received upfront surgery with a median survival time (MST) of 26.4 months. Tumor location (pancreatic head) (odds ratio [OR] 1.97, 95% confidence interval [CI] 1.14–3.40; P = 0.015), preoperative cancer antigen 19–9 (CA19–9) > 100 U/mL (OR 1.92, 1.31–2.80; P = 0.0009), and tumor size > 20 mm (OR 1.50, 1.02–2.19; P = 0.038) were identified as preoperative independent predictive risk factors for poor prognosis in patients with R-PDACs. In the patients with R-PDAC, 5-year survival was 60.7%, 21.5%, and 0% in patients with 0, 1 or 2, and 3 risk factors, respectively. There were significant differences in overall survival between the three groups (P < .0001).

Conclusions

A preoperative prognostic scoring system using preoperative tumor location, tumor size, and CA19-9 enables preoperative prediction of prognosis and facilitates selection of appropriate treatment for resectable pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74:2913–21.

    Article  CAS  PubMed  Google Scholar 

  2. Siegel RL, Miller KD and Jemal A. Cancer Statistics, 2017. CA: a cancer journal for clinicians. 2017.

  3. National Comprehensive Cancer Network. NCCN practice guidelines for pancreatic cancer, version 2. Available from: http://www.nccn.org/professionals/physician_gls/recently_ updated.asp.

  4. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310:1473–81.

    Article  CAS  PubMed  Google Scholar 

  5. Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, JASPAC 01 Study Group et al.. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016; 388:248–57.

    Article  CAS  PubMed  Google Scholar 

  6. Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004; 240:293–98.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Åkerberg D, Ansari D, Andersson R. Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas. World J Gastroenterol. 2016; 22:6424–33.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Sierzega M, Lenart M, Rutkowska M, Surman M, Mytar B, Matyja A, et al. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer. Ann Surg Oncol. 2017; 24:808–15.

    Article  PubMed  Google Scholar 

  9. Matsumoto I, Murakami Y, Shinzeki M, Asari S, Goto T, Tani M, et al. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study. Pancreatology. 2015; 15:674–80.

    Article  PubMed  Google Scholar 

  10. La Torre M, Nigri G, Cavallini M, Mercantini P, Ziparo V, Ramacciato G. The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2012; 19:2917–23.

    Article  PubMed  Google Scholar 

  11. Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M, et al. Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter. Medicine (Baltimore). 2016; 95:e3582. https://doi.org/10.1097/MD.0000000000003582.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Jamieson NB, Denley SM, Logue J, MacKenzie DJ, Foulis AK, Dickson EJ, et al. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2011; 18:2318–28.

    Article  PubMed  Google Scholar 

  13. Hirano S, Kondo S, Hara T, Ambo Y, Tanaka E, Shichinohe T, et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results. Ann Surg. 2007; 246:46–51.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Nakamura T, Hirano S, Noji T, Asano T, Okamura K, Tsuchikawa T, et al. Distal Pancreatectomy with en Bloc Celiac Axis Resection (Modified Appleby Procedure) for Locally Advanced Pancreatic Body Cancer: A Single-Center Review of 80 Consecutive Patients. Ann Surg Oncol. 2016; 23:969–75.

    Article  PubMed  Google Scholar 

  15. Sobin LH, Gospodarowicz MK, Wittekind Ch (eds). TNM Classification of Malignant Tumours. 7th ed. Wiley-Blackwell, Oxford, 2009

    Google Scholar 

  16. Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013; 14:317–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016; 17:801–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, et al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Ann Surg. 2018; 268:215–22.

    Article  PubMed  Google Scholar 

  19. Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, Dutch Pancreatic Cancer Group. et al; Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018; 105:946–58. Review.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007; 14:2088–96.

    Article  PubMed  Google Scholar 

  21. Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, et al. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer. 2011; 11:346.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H, et al. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012; 16:977–85.

    Article  PubMed  Google Scholar 

  23. Kim TH, Han SS, Park SJ, Lee WJ, Woo SM, Yoo T, et al. CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011; 81:e743–8.

    Article  CAS  PubMed  Google Scholar 

  24. Lau MK, Davila JA, Shaib YH. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas. 2010; 39:458–62.

    Article  PubMed  Google Scholar 

  25. Ling Q, Xu X, Ye P, Xie H, Gao F, Hu Q, et al. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma. Oncotarget. 2017; 8:15159–67.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, N-15 W-7, Kita-Ku, Sapporo, 060-8638, Japan

    Toru Nakamura, Toshimichi Asano, Keisuke Okamura, Takahiro Tsuchikawa, Soichi Murakami, Yo Kurashima, Yuma Ebihara, Takehiro Noji, Yoshitsugu Nakanishi, Kimitaka Tanaka, Toshiaki Shichinohe & Satoshi Hirano

Authors
  1. Toru Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshimichi Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keisuke Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takahiro Tsuchikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soichi Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yo Kurashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuma Ebihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takehiro Noji
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshitsugu Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kimitaka Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshiaki Shichinohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Satoshi Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work: Toru Nakamura, Toshimichi Asano, Keisuke Okamura, Takahiro Tsuchikawa, Takehiro Noji, Yoshitsugu Nakanishi, Kimitaka Tanaka, Soichi Murakami, Yuma Ebihara, Yo Kurashima, Toshiaki Shichinohe.

Drafting the work or revising it critically for important intellectual content: Toru Nakamura.

Final approval of the version to be submitted: Toru Nakamura, Satoshi Hirano.

Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: Toru Nakamura, Satoshi Hirano.

Corresponding author

Correspondence to Toru Nakamura.

Ethics declarations

This study was conducted in accordance with the ethical standards of the Committee on Human Experimentation of our institution and was approved by the Institutional Review Board of Hokkaido University Hospital (No. 017-0363).

Electronic supplementary material

ESM 1

(PPTX 56.9 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, T., Asano, T., Okamura, K. et al. A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?. J Gastrointest Surg 23, 990–996 (2019). https://doi.org/10.1007/s11605-018-3972-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-018-3972-x

Keywords

Search

Navigation